Body’s Own Gene Editing System Generates Leukemia Stem Cells

Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers —

Cancer stem cells are like zombies — even after a tumor is destroyed, they can keep coming back. These cells have an unlimited capacity to regenerate themselves, making more cancer stem cells and more tumors. Researchers at University of California San Diego School of Medicine have now unraveled how pre-leukemic white blood cell precursors become leukemia stem cells. The study, published June 9 in Cell Stem Cell, used human cells to define the RNA editing enzyme ADAR1’s role in leukemia, and find a way to stop it. … Read the Full Story from the UC San Diego Newsroom


Catriona H. M. Jamieson, MD, PhD

Catriona H. M. Jamieson, MD, PhD

The senior author of the study report is Catriona Jamieson, MD, PhD, Associate Professor of Medicine and Chief of the Division of Regenerative Medicine.

Dr. Jamieson is Deputy Director of the Sanford Stem Cell Clinical Center at UC San Diego Health, Director of the CIRM Alpha Stem Cell Clinic at UC San Diego School of Medicine and Director of Stem Cell Research at UC San Diego Moores Cancer Center.

UC San Diego Division of Regenerative Medicine coauthors include Sheldon Morris, MD, MPH, Data Management Lead for the UC San Diego CIRM Alpha Stem Cell Clinic; co-first authors Maria Anna Zipeto and Angela C. Court, Anil Sadarangani, Nathaniel P. Delos Santos, Larisa Balaian, Gabriel Pineda, Cayla N. Mason, Ifat Geron, Daniel J. Goff, Russell Wall, Leslie A. Crews and Qingfei Jiang.

Read the study report (UC San Diego only)

Visit the Jamieson Lab Website

Drug Targets Hard-to-Reach Leukemia Stem Cells Responsible for Relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive – and thus vulnerable – to a novel cancer stem cell-targeting drug currently under development. … Read the full story from the UCSD Newsroom


Catriona H. M. Jamieson, MD, PhDPrincipal investigator of the study is Catriona H. M. Jamieson, MD, PhD, associate professor of medicine in the Division of Hematology-Oncology and director of stem cell research at the UC San Diego Moores Cancer Center.

Dr. Jamieson is on the steering committee for the Moores Cancer Center’s My Answer to Cancer initiative for personalized cancer therapy. She is a member of the faculty in the UCSD Biomedical Sciences Graduate Program.

Citation for the report: Goff DJ, Recart AC, Sadarangani A, Chun H-J, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao K-H, Shazand K, Wentworth P, Smith KM, Jamieson CAM, Morris SR, Messer K, S.B. Goldstein LSB, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, and Jamieson CHM. (2013) A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition. Cell Stem Cell 10.1016/j.stem.2012.12.011, online January 17, 2013.

More about Dr. Jamieson and her work: